# US 2024/0199706 A1 · Immunomodulatory complex and uses thereof for therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199706 A1
- Document ID: US20240199706A1
- Status: Published application
- Kind: A1
- Application number: 17/999,898
- Filed: 2021-05-28
- Published: 2024-06-20
- Earliest claimed: 2020-05-28
- Assignees: Commissariat A L'energie Atomique Et Aux Energies Alternatives
- Applicants: Commissariat A L'energie Atomique Et Aux Energies Alternatives
- Inventors: Michel LEONETTI; Alexandra SAVATIER; Celine COUSIN; Culina SLOBODAN
- Web page: https://patentgrep.com/patent/US20240199706A1

## CPC

- A61K 38/162: {from virus}
- C07K 14/163: {Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/45: Transferases (2)
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 37/04: Immunostimulants
- C07K 14/34: from Corynebacterium (G)
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- C07K 14/7056: {Lectin superfamily, e.g. CD23, CD72}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a molecular complex consisting of at least one ligand of a sulphated sugar of the glycosaminoglycan family linked to at least one ligand of a surface molecule of antigen-presenting cells or NK or NKT cells, for use as an immunomodulatory drug, in particular in the immunotherapy of cancer and infectious diseases.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

An immunomodulatory composition, comprising at least one molecular complex,
wherein said complex consists of at least one ligand of a sulfated sugar of the glycosaminoglycan family (first ligand) and at least one ligand of a surface molecule of antigen-presenting cells or of NK or NKT cells (second ligand), and
wherein said ligands are bonded to one another and said complex is free of a specific antigen of the disease to be treated,
and at least one pharmaceutically acceptable carrier, a carrier substance and/or an adjuvant.

### Claim 18 (depends on 17)

The composition according to claim 17, wherein the first ligand is a heparan sulfate-binding peptide selected from the group consisting of: a peptide derived from the HIV Tat protein, comprising at least the basic region Tat49-57 (SEQ ID NO: 3) such as the peptides Tat49-57 (SEQ ID NO: 3), Tat37-57 (SEQ ID NO: 8) and Tat22-57C(22-37)S (SEQ ID NO:9); an R7 to R11 polyarginine peptide; and a peptide comprising the R domain of the diphtheria toxin (SEQ ID NO: 5) or at least the fragment DT453-467 (SEQ ID NO 7) of said domain, comprising the heparan sulfate binding region.

### Claim 19 (depends on 17)

The composition according to claim 17, wherein the second ligand targets a surface molecule of antigen-presenting cells selected from the group consisting of: C-type lectin receptors, membrane-bound immunoglobulins, receptors for the constant region of immunoglobulins, and immune checkpoint molecules and ligands thereof.

### Claim 20 (depends on 17)

The composition according to claim 17, wherein the second ligand is selected from the group consisting of: (i) antibodies directed against said surface molecules of antigen-presenting cells or of NK or NKT cells and fragments thereof containing at least the paratope; (ii) immunoglobulins, and fragments thereof comprising at least the Fc region; and (iii) proteins and protein fragments which bind to the Fc and/or Fab region of the antibodies.

### Claim 21 (depends on 20)

The composition according to claim 20, wherein the immunoglobulins are IgG.

### Claim 22 (depends on 20)

The composition according to claim 20, wherein the proteins and protein fragments which bind to the Fc and/or Fab region of the antibodies are selected from the group consisting of: protein A of S. aureus, the BB fragment thereof (SEQ ID NO: 1) and the ZZ derivative thereof (SEQ ID NO: 2).

### Claim 23 (depends on 17)

The composition according to claim 17, wherein the at least one molecular complex is in the form of oligomers or a mixture of monomers and oligomers.

### Claim 24 (depends on 17)

The composition according to claim 17, wherein the at least one molecular complex consists of a fusion protein between the first and the second ligand.

### Claim 25 (depends on 24)

The composition according to claim 24, wherein the fusion protein comprises a first ligand selected from: Tat49-57 (SEQ ID NO: 3), Tat37-57 (SEQ ID NO: 8), Tat22-57C(22-37)S (SEQ ID NO 9), the R domain of the diphtheria toxin (SEQ ID NO: 5) or the fragment DT453-467 (SEQ ID NO 7) and a second ligand selected from: the BB fragment of the protein A (SEQ ID NO: 1) or the ZZ derivative thereof (SEQ ID NO: 2).

### Claim 26 (depends on 17)

The composition according to claim 17, wherein the second ligand is an antibody or an antibody fragment and the first ligand forms a fusion protein with an immunoglobulin-binding element.

### Claim 27 (depends on 26)

The composition according to claim 26, wherein said fusion protein comprises a first ligand selected from Tat49-57 (SEQ ID NO: 3), Tat37-57 (SEQ ID NO: 8), Tat22-57C(22-37)S (SEQ ID NO 9), the R domain of the diphtheria toxin (SEQ ID NO: 5) or the fragment DT453-467 (SEQ ID NO 7) and an immunoglobulin-binding element selected from the BB fragment of the protein A (SEQ ID NO: 1) or the ZZ derivative thereof (SEQ ID NO: 2).

### Claim 28 (depends on 26)

The composition according to claim 26, wherein said fusion protein comprises a first ligand selected from Tat49-57 (SEQ ID NO: 3), Tat37-57 (SEQ ID NO: 8), Tat22-57C(22-37)S (SEQ ID NO 9), the R domain of the diphtheria toxin (SEQ ID NO: 5) or the fragment DT453-467 (SEQ ID NO 7) and an immunoglobulin-binding element which is the BB fragment of the protein A (SEQ ID NO: 1) and said fusion protein is complexed to the second ligand which consists of a whole immunoglobulin.

### Claim 29 (depends on 26)

The composition according to claim 26, wherein said fusion protein comprises a first ligand selected from Tat49-57 (SEQ ID NO: 3), Tat37-57 (SEQ ID NO: 8), Tat22-57C(22-37)S (SEQ ID NO 9), the R domain of the diphtheria toxin (SEQ ID NO: 5) or the fragment DT453-467 (SEQ ID NO 7), and an immunoglobulin-binding element selected from the BB fragment of the protein A (SEQ ID NO: 1) or the ZZ derivative thereof (SEQ ID NO: 2) and wherein said fusion protein is complexed to the second ligand which is selected from an anti-RFcgamma I, II and/or III, anti-DEC-205, anti-DC-SIGN, anti-CD74, anti-CD275, anti-CD56, anti-CD335, anti-CD336, anti-CTLA-4, anti-PD-L1, anti-OX40 antibody, or a fragment of the preceding antibodies comprising at least the paratope.

### Claim 30 (depends on 17)

The composition according to claim 17, which is an immunostimulatory composition.

### Claim 31 (depends on 17)

The composition according to claim 17, which is for activating antigen-presenting cells, for activating NK or NKT cells, and/or for activating the secretion of the cytokines IL-6 and/or IL-12

### Claim 32 (depends on 31)

The composition according to claim 31, wherein the antigen-presenting cells are dendritic cells or monocytes.

### Claim 33 (depends on 17)

The composition according to claim 17, wherein the adjuvant is a CpG oligodeoxynucleotide, polyinosinic-polycytidylic acid or a mixture of CpG oligodeoxynucleotide(s) and polyinosinic:polycytidylic acid, and/or the carrier substance is a nanoparticle.

### Claim 34 (depends on 17)

The composition according to claim 17, further comprising at least one immune checkpoint inhibitor.

### Claim 35 (depends on 34)

The composition according to claim 34, wherein the immune checkpoint inhibitor is chosen from an anti-PD-1, an anti-PDL-1 and an anti-CTLA4.

### Claim 36 (depends on 17)

A method of immunotherapy of cancer or infectious diseases, comprising the administration to a subject in need thereof of a therapeutically effective amount of the composition according to claim 17.
